NCT06282510 Nasal Antisepsis for C. Auris Prevention
| NCT ID | NCT06282510 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Mary K Hayden |
| Condition | Candida Auris Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-01-29 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 120 participants in total. It began in 2024-01-29 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
Eligibility Criteria
Inclusion Criteria: * History of C. auris colonization or infection * Patient in a participating facility Exclusion Criteria: * History of severe allergy to iodine-based products, defined as anaphylaxis or rash * Currently breastfeeding or pregnant * Non-English language speaking
Contact & Investigator
Mary K. Hayden, MD
PRINCIPAL INVESTIGATOR
Rush University Medical Center
Frequently Asked Questions
Who can join the NCT06282510 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Candida Auris Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06282510 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06282510 currently recruiting?
Yes, NCT06282510 is actively recruiting participants. Contact the research team at sarah_e_sansom@rush.edu for enrollment information.
Where is the NCT06282510 trial being conducted?
This trial is being conducted at Chicago, United States, Chicago, United States, Hinsdale, United States.
Who is sponsoring the NCT06282510 clinical trial?
NCT06282510 is sponsored by Mary K Hayden. The principal investigator is Mary K. Hayden, MD at Rush University Medical Center. The trial plans to enroll 120 participants.